Pharmacologically relevant concentrations of berberine transiently stimulate dihydrotestosterone-inducible androgen receptor-mediated luciferase activity in human prostate cancer cells
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F18%3A73587073" target="_blank" >RIV/61989592:15310/18:73587073 - isvavai.cz</a>
Výsledek na webu
<a href="http://tcr.amegroups.com/article/view/20299/16017" target="_blank" >http://tcr.amegroups.com/article/view/20299/16017</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21037/tcr.2018.03.31" target="_blank" >10.21037/tcr.2018.03.31</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Pharmacologically relevant concentrations of berberine transiently stimulate dihydrotestosterone-inducible androgen receptor-mediated luciferase activity in human prostate cancer cells
Popis výsledku v původním jazyce
Background: Herbal medicines containing berberine have a wide spectrum of usage. However, the effect on androgen receptor (AR) activity at plasmatic relevant concentrations is omitted. Therefore, the effect of berberine on AR activity in prostate cancer cell lines was investigated. Methods: We used the reporter gene assay (RGA) and polymerase chain reaction (qPCR) for monitoring the activity of AR. Moreover, we monitored the proliferation of two prostate cancer cell lines treated with Berberine. Results: Berberine significantly potentiated dihydrotestosterone (DHT)-inducible AR-dependent luciferase activity in RGA. It also significantly decreased basal KLK3 mRNA level in 22Rv1 cells, but DHT-inducible KLK3 mRNA was not affected in androgen-independent (22Rv1) or androgen-dependent (LNCaP) cells. Proliferation of both cell lines was significantly inhibited by 100 and 1,000 nM concentrations in similar manner and Berberine increased Annexin V staining, suggesting an apoptotic event. Conclusions: Berberine inhibits proliferation of prostatic cell lines at pharmacologically reachable concentrations but with no apparent link to androgen receptor-driven target gene expression.
Název v anglickém jazyce
Pharmacologically relevant concentrations of berberine transiently stimulate dihydrotestosterone-inducible androgen receptor-mediated luciferase activity in human prostate cancer cells
Popis výsledku anglicky
Background: Herbal medicines containing berberine have a wide spectrum of usage. However, the effect on androgen receptor (AR) activity at plasmatic relevant concentrations is omitted. Therefore, the effect of berberine on AR activity in prostate cancer cell lines was investigated. Methods: We used the reporter gene assay (RGA) and polymerase chain reaction (qPCR) for monitoring the activity of AR. Moreover, we monitored the proliferation of two prostate cancer cell lines treated with Berberine. Results: Berberine significantly potentiated dihydrotestosterone (DHT)-inducible AR-dependent luciferase activity in RGA. It also significantly decreased basal KLK3 mRNA level in 22Rv1 cells, but DHT-inducible KLK3 mRNA was not affected in androgen-independent (22Rv1) or androgen-dependent (LNCaP) cells. Proliferation of both cell lines was significantly inhibited by 100 and 1,000 nM concentrations in similar manner and Berberine increased Annexin V staining, suggesting an apoptotic event. Conclusions: Berberine inhibits proliferation of prostatic cell lines at pharmacologically reachable concentrations but with no apparent link to androgen receptor-driven target gene expression.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
<a href="/cs/project/GBP303%2F12%2FG163" target="_blank" >GBP303/12/G163: Centrum interakcí potravních doplňků s léčivy a nutrigenetiky</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2018
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Translational Cancer Research
ISSN
2218-676X
e-ISSN
—
Svazek periodika
7
Číslo periodika v rámci svazku
2
Stát vydavatele periodika
CN - Čínská lidová republika
Počet stran výsledku
8
Strana od-do
383-390
Kód UT WoS článku
000431844200018
EID výsledku v databázi Scopus
2-s2.0-85046467272